Skip Nav Destination

First Edition

Research Article November 15 2024

Cerebrospinal Fluid Attenuates the Efficacy of Methotrexate against Acute Lymphoblastic Leukemia Cells

Jongseok Kang,Jason Ostergaard,Xiaohong Wang,Peter M. Gordon

Research Article November 15 2024

Single-cell and spatial characterization of plasmablast-like lymphoma cells in primary central nervous system lymphoma

Hiroki Kobayashi,Ryota Chijimatsu,Yusuke Naoi,Yoshihiro Otani,Ryo Mizuta,Kentaro Fujii,Joji Ishida,Hiroyuki Murakami,Hideki Ujiie,Kazuhiro Ikeuchi,Tomohiro Urata,Keisuke Seike,Hideaki Fujiwara,Noboru Asada,Nobuharu Fujii,Ken-ichi Matsuoka,Yasuharu Sato,Maeda Yoshinobu,Daisuke Ennishi

View article

Supplementary data

Research Article November 2 2024

Pralatrexate Injection Combined with Oral Leucovorin for Mucositis Management in the Treatment of Peripheral and Cutaneous T-Cell Lymphomas–Results from a Multicenter Phase 2 Trial

Swaminathan P. Iyer,Shaker Dakhil,Michi M. Shinohara,Jasmine Zain,Mark Acosta,Francine Foss

View article

Research Article November 2 2024

A phase 1 study of interleukin-15 in combination with mogamulizumab in relapsed and refractory T-cell malignancies

Max J. Gordon,Sigrid Dubois,Milos D. Miljkovic,Samuel Ng,Bonita Bryant,Rahul Lakhotia,Christopher Melani,Stefania Pittaluga,Kevin Conlon,Thomas Waldmann,Louis M. Staudt,Wyndham H. Wilson,Mark Roschewski

View article

Research Article November 2 2024

JAK1/2 Inhibitor Ruxolitinib for the Treatment of Systemic Chronic Active Epstein-Barr Virus Disease: A Phase II Study

Yu Uemura,Masahide Yamamoto,Masataka Ishimura,Hirokazu Kanegane,Akihisa Sawada,Akihiro Hirakawa,Ken-Ichi Imadome,Mayumi Yoshimori,Masashi Nagata,Kouhei Yamamoto,Norio Shimizu,Ryuji Koike,Ayako Arai

View article

Supplementary data

Research Article November 2 2024

Addition of navitoclax to ruxolitinib in patients with myelofibrosis with progression or suboptimal response

Naveen Pemmaraju,Tim C.P. Somervaille,Francesca Palandri,Claire Harrison,Rami S. Komrokji,Andrew Perkins,Rosa M. Ayala Diaz,David Lavie,Akihiro Tomita,Yang Feng,Qin Qin,Jason Harb,Akshanth R. Polepally,Jalaja Potluri,Jacqueline S. Garcia

View article

Supplementary data

Research Article October 24 2024

Pharmacological targeting of CBX7 alters the epigenetic landscape and induces differentiation of leukemic cells

Anne P. de Groot,Chelsea R. Wilson,Ellen Weersing,Jacobine S. Pouw,Albertina Dethmers-Ausema,Huong Nguyen,Evan F. W. Chen,Alok Shaurya,Linda Smit,Fraser Hof,Gerald de Haan

View article

Supplementary data

Research Article October 24 2024

Enitociclib, a selective CDK9 inhibitor: in vitro and in vivo preclinical studies in multiple myeloma

Son Tran,Patrick Sipila,Melanie M. Frigault,Beatrix Stelte-Ludwig,Amy J. Johnson,Joseph Birkett,Raquel Izumi,Ahmed Hamdy,Ranjan Maity,Nizar J. Bahlis,Paola Neri,Aru Narendran

View article

Supplementary data

Research Article October 24 2024

Low platelet counts and low CD4/CD8 ratios at apheresis increase the risk of CAR-T cell manufacturing failure in myeloma

View article

Supplementary data

Research Article October 22 2024

Real-world characteristics, treatment patterns, and outcomes of patients with 2 or more LOTs for CLL/SLL in the US

Matthew S. Davids,Jacob Ambrose,Enrico de Nigris,Jennifer Prescott,Siyang Leng,Mohammed Farooqui,Shravanthi R. Gandra,Christina M Zettler,Laura L. Fernandes,Ching-Kun Wang,Mazyar Shadman

View article

Supplementary data

Research Article October 14 2024

Predictors of Response to Venetoclax and Therapeutic Potential of CDK7 Inhibition in Multiple Myeloma

View article

Supplementary data

Research Article October 13 2024

Development and characterization of a low-affinity humanized CD19-chimeric antigen receptor for B cell malignancies

Lawrence A. Stern,Vibhuti Vyas,Laura Lim,Christian Huynh,Ryan Urak,Ruby Espinosa,Zhiqiang Wang,Michalina Silva Thiel,John C Williams,Stephen J Forman,Christine E Brown,Xiuli Wang

View article

Supplementary data

Research Article October 12 2024

Deciphering MARCH5’s Impact on Multiple Myeloma: Insights into Autophagy Regulation and AKT-FOXO3 Signaling

Hamed Bashiri,Ahad Khalilnezhad,Haruhito Totani,Joe Yeong,Tae-Hoon Chung,Felicia Wee,Yuezhen Xue,Zhen Wei Neo,Li Yen Chong,Wee Joo Chng,Atsushi Watanabe,Siok-Bian Ng,The Phyu,Toshio Suda

View article

Brief Report October 12 2024

Pathogenic germline variants in a prospective multi-center cohort of patients with multiple myeloma

Julia Erin Wiedmeier-Nutor,Michael A. Golafshar,Katie L. Kunze,Edward D. Esplin,Robert L. Nussbaum,Brandie Heald,A. Keith Stewart,N. Jewel Samadder,Leif Bergsagel,Rafael Fonseca

View article

Supplementary data

Research Article September 16 2024

Diagnostic Genomic Analysis is Prognostic in AYA ALL Patients Treated on a MRD-Stratified Pediatric Protocol

DT Yeung,LN Eadie,J Rehn,SL Heatley,BJ McClure,EC Page,CE Schutz,MP Osborn,T Trahair,R Sutton,MJ Henderson,J Kwan,S Mapp,L Dalla-Pozza,K Bradstock,M Greenwood,DL. White

View article

Supplementary data

First Edition

Cerebrospinal Fluid Attenuates the Efficacy of Methotrexate against Acute Lymphoblastic Leukemia Cells

Single-cell and spatial characterization of plasmablast-like lymphoma cells in primary central nervous system lymphoma

Pralatrexate Injection Combined with Oral Leucovorin for Mucositis Management in the Treatment of Peripheral and Cutaneous T-Cell Lymphomas–Results from a Multicenter Phase 2 Trial

A phase 1 study of interleukin-15 in combination with mogamulizumab in relapsed and refractory T-cell malignancies

JAK1/2 Inhibitor Ruxolitinib for the Treatment of Systemic Chronic Active Epstein-Barr Virus Disease: A Phase II Study

Addition of navitoclax to ruxolitinib in patients with myelofibrosis with progression or suboptimal response

Pharmacological targeting of CBX7 alters the epigenetic landscape and induces differentiation of leukemic cells

Enitociclib, a selective CDK9 inhibitor: in vitro and in vivo preclinical studies in multiple myeloma

Low platelet counts and low CD4/CD8 ratios at apheresis increase the risk of CAR-T cell manufacturing failure in myeloma

Real-world characteristics, treatment patterns, and outcomes of patients with 2 or more LOTs for CLL/SLL in the US

Predictors of Response to Venetoclax and Therapeutic Potential of CDK7 Inhibition in Multiple Myeloma

Development and characterization of a low-affinity humanized CD19-chimeric antigen receptor for B cell malignancies

Deciphering MARCH5’s Impact on Multiple Myeloma: Insights into Autophagy Regulation and AKT-FOXO3 Signaling

Pathogenic germline variants in a prospective multi-center cohort of patients with multiple myeloma

Diagnostic Genomic Analysis is Prognostic in AYA ALL Patients Treated on a MRD-Stratified Pediatric Protocol

ASH Publications

American Society of Hematology

First Edition

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only